What development phase is Amipaque in?

Amipaque is FDA-approved (marketed).

What is the generic name of Amipaque?

METRIZAMIDE is the generic (nonproprietary) name of Amipaque.

Last reviewed 2026-04-20 · How we verify

Amipaque (METRIZAMIDE)

FDA-approved approved Small molecule Quality 10/100

Amipaque (Metrizamide) is a small molecule contrast agent in the metrizamide class, originally developed by Nyegaard & Co. It was FDA approved in 1978 for use in myelography and other imaging procedures. Amipaque is off-patent and has no active Orange Book patents, indicating it is available as a generic medication. However, there are currently no generic manufacturers listed. As a result, Amipaque remains a branded medication.

At a glance

Generic name	METRIZAMIDE
Drug class	metrizamide
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved
First approval	1978

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions